Contact
searchSearch
HMP Global
Login

Myelofibrosis Excellence Forum

Myelofibrosis
Excellence Forum
Leaders in the field sharing authoritative insights and institutional best practices.

Prithviraj Bose, MD
Videos
Zilurgisertib Alone or Combined With Ruxolitinib Well-Tolerated Among Patients With Myelofibrosis
07/25/2024
Prithviraj Bose, MD, shares results from an ongoing study that demonstrate that zilurgisertib as monotherapy or in combination with ruxolitinib had a favorable tolerance profile among patients with myelofibrosis.
Prithviraj Bose, MD, shares results from an ongoing study that demonstrate that zilurgisertib as monotherapy or in combination with ruxolitinib had a favorable tolerance profile among patients with myelofibrosis.
Prithviraj Bose, MD, shares...
07/25/2024
Oncology
John Mascarenhas, MD
Videos
Examining Real-World Outcomes Among Patients With Myelofibrosis Treated With Pacritinib
07/17/2024
John Mascarenhas, MD, shares results of a retrospective study on the real-world treatment outcomes among patients with myelofibrosis who were treated with pacritinib.
John Mascarenhas, MD, shares results of a retrospective study on the real-world treatment outcomes among patients with myelofibrosis who were treated with pacritinib.
John Mascarenhas, MD, shares...
07/17/2024
Oncology
Claire Harrison, MD, FRCP, Guy’s and St. Thomas’ NHS Foundation Trust
Q&As
Elritercept Well-Tolerated, Demonstrates Potential Efficacy for the Treatment of Patients With Myelofibrosis
07/11/2024
Claire Harrison, MD, FRCP, shares results of the ongoing phase 2 RESTORE trial in which elritercept was generally well-tolerated and demonstrated potential efficacy for treating patients with myelofibrosis.
Claire Harrison, MD, FRCP, shares results of the ongoing phase 2 RESTORE trial in which elritercept was generally well-tolerated and demonstrated potential efficacy for treating patients with myelofibrosis.
Claire Harrison, MD, FRCP,...
07/11/2024
Oncology
Aaron Gerds, MD
Videos
Novel Updates in Frontline Myelofibrosis Treatment Research
06/25/2024
Aaron Gerds, MD, discusses data from the MANIFEST-2 and TRANSFORM-1 trials exploring first-line treatment options for patients with myelofibrosis, as well as analyzes the establishment of optimal clinical trial end points.
Aaron Gerds, MD, discusses data from the MANIFEST-2 and TRANSFORM-1 trials exploring first-line treatment options for patients with myelofibrosis, as well as analyzes the establishment of optimal clinical trial end points.
Aaron Gerds, MD, discusses data...
06/25/2024
Oncology
Aaron Gerds, MD
Videos
Examining Luspatercept Efficacy for Anemia and Transfusion Burden Among Patients With Myelofibrosis
06/24/2024
Aaron Gerds, MD, presents insights into data from a study in which luspatercept improved anemia and transfusion burden for patients with myelofibrosis, and explains next steps for investigating luspatercept in further clinical trials.
Aaron Gerds, MD, presents insights into data from a study in which luspatercept improved anemia and transfusion burden for patients with myelofibrosis, and explains next steps for investigating luspatercept in further clinical trials.
Aaron Gerds, MD, presents...
06/24/2024
Oncology
Marina Kremyanskaya, MD, PhD, Icahn School of Medicine
Videos
Rusfertide Improves Hematocrit Control and Decreases Use of Phlebotomy Among Patients With PV
05/28/2024

Featuring Marina Kremyanskaya, MD, PhD

Featuring Marina Kremyanskaya, MD, Ph...
Marina Kremyanskaya, MD, PhD, shares study results from the REVIVE trial in which rusfertide demonstrated improved hematocrit control and decreased the use of phlebotomy among patients with polycythemia vera.
Marina Kremyanskaya, MD, PhD, shares study results from the REVIVE trial in which rusfertide demonstrated improved hematocrit control and decreased the use of phlebotomy among patients with polycythemia vera.
Marina Kremyanskaya, MD, PhD,...
05/28/2024
Oncology
Eytan M Stein, MD
Q&As
Preventing Transformation and Adverse Events Among Patients With Myelofibrosis
03/07/2024

Featuring Eytan M Stein, MD

Featuring Eytan M Stein, MD
Eytan M Stein, MD, shares expert insights on preventing transformation and reducing the symptom burden of adverse events among patients with myelofibrosis.
Eytan M Stein, MD, shares expert insights on preventing transformation and reducing the symptom burden of adverse events among patients with myelofibrosis.
Eytan M Stein, MD, shares expert...
03/07/2024
Oncology
Eytan M Stein, MD
Q&As
Evaluating Efficacy and Safety of Pelabresib Among Patients With MDS/MPN
03/07/2024

Featuring Eytan M Stein, MD

Featuring Eytan M Stein, MD
Eytan M Stein, MD, discusses findings from the MANIFEST trial which evaluated the efficacy and safety of pelabresib among patients with acute leukemia, high-risk myelodysplastic syndrome, or MDS/MPN.
Eytan M Stein, MD, discusses findings from the MANIFEST trial which evaluated the efficacy and safety of pelabresib among patients with acute leukemia, high-risk myelodysplastic syndrome, or MDS/MPN.
Eytan M Stein, MD, discusses...
03/07/2024
Oncology
Jie Jin, MD, PhD
Videos
Assessing Efficacy of Jaktinib Among Ruxolitinib-Intolerant Patients With Myelofibrosis
02/21/2024
Jie Jin, MD, PhD, shares results from a phase 2 study that explored the efficacy of Janus kinase inhibitor jaktinib treatment for ruxolitinib-intolerant patients with myelofibrosis.
Jie Jin, MD, PhD, shares results from a phase 2 study that explored the efficacy of Janus kinase inhibitor jaktinib treatment for ruxolitinib-intolerant patients with myelofibrosis.
Jie Jin, MD, PhD, shares results...
02/21/2024
Oncology
Francesca Palandri, MD, PhD
Q&As
Encouraging Developments in Treatment Strategy for Patients With Myelofibrosis
02/21/2024
Francesca Palandri, MD, PhD, discusses future possibilities and new breakthroughs in treatment strategies for patients with myelofibrosis, such as expanding treatment options for high-risk patients and more deeply considering the biology of...
Francesca Palandri, MD, PhD, discusses future possibilities and new breakthroughs in treatment strategies for patients with myelofibrosis, such as expanding treatment options for high-risk patients and more deeply considering the biology of...
Francesca Palandri, MD, PhD,...
02/21/2024
Oncology

Recent News

News
Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer
11/14/2024
According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.
According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.
According to a retrospective...
11/14/2024
Oncology
News
Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer
11/14/2024
According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.
According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.
According to results from the...
11/14/2024
Oncology
News
Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma
11/13/2024
Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.
Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.
Results from the phase 2...
11/13/2024
Oncology
News
Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas
11/12/2024
According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...
According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...
According to a phase 2b trial,...
11/12/2024
Oncology
News
Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer
11/12/2024
According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.
According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.
According to final results from...
11/12/2024
Oncology
News
Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer
11/11/2024
According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.
According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.
According to results from a...
11/11/2024
Oncology
FDA Approval
FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia
11/08/2024
On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
On November 8, 2024, the FDA...
11/08/2024
Oncology
News
Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer
11/07/2024
While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.
While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.
While naporafenib plus...
11/07/2024
Oncology
News
Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer
11/06/2024
According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.
According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.
According to results from a...
11/06/2024
Oncology
News
Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma
11/05/2024
A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.
A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.
A single-center real-world study...
11/05/2024
Oncology

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use